Evotec H1 FY26 adjusted EBITDA loss widens to EUR 42.7 million; revenue drops 19.2% to EUR 300.1 million
Reuters2026/08/13 05:28- Evotec SE revenue fell 19.2% to EUR 300.1 million in H1 2026.
- Adjusted EBITDA loss widened to EUR 42.7 million from a near-breakeven loss a year earlier.
- Net loss widened to EUR 168.6 million, driven by EUR 98.9 million in Horizon-related reorganization costs and a EUR 42.3 million impairment.
- Discovery & Preclinical Development revenue slipped 15.2% to EUR 228.1 million; Just-Evotec Biologics dropped 29.3% to EUR 72.3 million.
- Guidance reaffirmed for 2026 revenue of EUR 570 million to EUR 610 million, adjusted EBITDA of negative EUR 70 million to negative EUR 105 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
At a sensitive moment of the "bond market storm," the market focuses on today's 30-year Japanese government bond auction.
Japan’s 30-year government bond yield has risen to 4.155%, approaching a historic high. The 30-year bond auction scheduled for Thursday is drawing significant attention. Analysts generally expect a weak result and warn that if the auction goes poorly, it could put reverse pressure on US Treasuries, prompting a repricing of the global fixed income market and potentially becoming a new trigger for rising global borrowing costs.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
